Daily MaverickLABOUR (IN)JUSTICE: Aspen Pharmacare loses appeal bid in man’s decade-long fight over unfair dismissalInquirer3 centenarians, 6 other elderly in Ilocos Norte get P360,000 in cashThe Jerusalem PostDemocrats secure biggest House majority since 1992 with 258 seats한겨레미 민주당, 하원 최소 258석 확보…1992년 이후 최다ZDF heuteEntdecken Sie das ZDF-NachrichtenstudioIl Fatto QuotidianoIl Career Grand Slam, poi il grave infortunio e ora il trionfo alle Finals: Alcaraz ha ritrovato sé stesso a Torino | Il commentoABC NewsEquipment outage in Atlanta causes over 1,600 Delta flight delaysThe Sydney Morning HeraldWorld Cup winner faints mid-interviewCBS Sports'Sunday Night Football' in Mexico City prediction, odds, time: 49ers vs. Vikings picks by expert on 40-17 rollBBC News'World's best could've lost 4-0' - but should Man Utd have done more at Anfield?The Guardian AustraliaAustralian politics live: Labor to extend PBS medicine freeze to 2030; Bowen ‘failed’ on Cop, Hume saysBusiness AMFrankrijk bevestigt samenwerking met Oekraïne rond geavanceerd SAMP/T NG-luchtverdedigingssysteem
The Daily Newsstand · Free, Always
Sunday, November 22, 2026

Judge approves $7.25bn settlement for Roundup weedkiller cancer claims

Translate

A Missouri judge on Friday approved a $7.25bn (£5.5bn) settlement stemming from lawsuits ⁠alleging that Bayer's weedkiller Roundup causes cancer.

Judge Timothy Boyer said the settlement was "fair, reasonable, and adequate".

Bayer, the German biotech giant, had proposed paying the $7.25bn to definitively resolve a legal battle in the US.

The nationwide settlement will be paid to Roundup users who are already sick with non-Hodgkin lymphoma and those who fall ill in the future.

The company has already paid roughly $10bn to resolve Roundup-related litigation.

The settlements to participants range from $10,000 to $165,000, depending on how frequently they used the product, when they were diagnosed with the cancer and how severe their illness was.

"[Friday's] final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice," said Christopher Seeger, a court-appointed counsel for cancer patients in the case.

Bayer will make annual payments into a fund for up to 21 years, totalling up to $7.25bn.

Some attorneys objected to the settlement funds, arguing they were insufficient, but the judge said he did not want to delay payouts to sick victims.

Bayer denies that its Roundup product causes cancer.

The settlement comes after the Supreme Court in June ruled in favour of Bayer, overturning a $1.25m settlement for a Missouri man who said Roundup and its ingredient glyphosate was to blame for his non-Hodgkin lymphoma.

The court ruled 7-2, saying Bayer cannot be sued in state courts because federal regulations do not mandate a cancer warning label.

The company has faced thousands of claims in US state and federal courts from people alleging they developed cancer after using the product.

Monsanto developed Roundup in the 1970s. Its active ingredient, glyphosate, was identified by the International Agency for Research on Cancer, a unit of the World Health Organisation, in 2015 as a probable human carcinogen.

Bayer and some other regulators, including the US Environmental Protection Agency, have disputed those findings.

But the issue has forced the company through years of costly litigation in the US, as juries in several states have awarded billions of dollars to herbicide users.

Add MyJoyOnline as a preferred source on GoogleSee more of our stories when you search on Google. (opens in a new tab)

DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.

Tags:  

DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.

View the original on MyJoyOnline →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.